Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 169 to 176 of 176 entries
Sorted by: Best Match Show Resources per page
Altered lipid metabolism marks glioblastoma stem and non-stem cells in separate tumor niches.

Acta neuropathologica communications

Shakya S, Gromovsky AD, Hale JS, Knudsen AM, Prager B, Wallace LC, Penalva LOF, Brown HA, Kristensen BW, Rich JN, Lathia JD, Brown JM, Hubert CG.
PMID: 34059134
Acta Neuropathol Commun. 2021 May 31;9(1):101. doi: 10.1186/s40478-021-01205-7.

Glioblastoma (GBM) displays marked cellular and metabolic heterogeneity that varies among cellular microenvironments within a tumor. Metabolic targeting has long been advocated as a therapy against many tumors including GBM, but how lipid metabolism is altered to suit different...

Cite
Shakya S, Gromovsky AD, Hale JS, et al. Altered lipid metabolism marks glioblastoma stem and non-stem cells in separate tumor niches. Acta Neuropathol Commun. 2021;9(1):101doi: 10.1186/s40478-021-01205-7.
Shakya, S., Gromovsky, A. D., Hale, J. S., Knudsen, A. M., Prager, B., Wallace, L. C., Penalva, L. O. F., Brown, H. A., Kristensen, B. W., Rich, J. N., Lathia, J. D., Brown, J. M., & Hubert, C. G. (2021). Altered lipid metabolism marks glioblastoma stem and non-stem cells in separate tumor niches. Acta neuropathologica communications, 9(1), 101. https://doi.org/10.1186/s40478-021-01205-7
Shakya, Sajina, et al. "Altered lipid metabolism marks glioblastoma stem and non-stem cells in separate tumor niches." Acta neuropathologica communications vol. 9,1 (2021): 101. doi: https://doi.org/10.1186/s40478-021-01205-7
Shakya S, Gromovsky AD, Hale JS, Knudsen AM, Prager B, Wallace LC, Penalva LOF, Brown HA, Kristensen BW, Rich JN, Lathia JD, Brown JM, Hubert CG. Altered lipid metabolism marks glioblastoma stem and non-stem cells in separate tumor niches. Acta Neuropathol Commun. 2021 May 31;9(1):101. doi: 10.1186/s40478-021-01205-7. PMID: 34059134; PMCID: PMC8166002.
Copy Download .nbib Format: NLM
Incidence of positive SARS-CoV-2 PCR after COVID-19 vaccination with up to eight months of follow-up: Real life data from the Capital Region of Denmark.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Heftdal LD, Schultz M, Lange T, Knudsen AD, Fogh K, Hasselbalch RB, Linander CB, Kallemose T, Bundgaard H, Grønbæk K, Valentiner-Branth P, Iversen K, Nielsen SD.
PMID: 35015858
Clin Infect Dis. 2022 Jan 07; doi: 10.1093/cid/ciac012. Epub 2022 Jan 07.

BACKGROUND: COVID-19 vaccines are implemented worldwide in efforts to curb the pandemic. This study investigates the risk of a positive SARS-CoV-2 RT-PCR test following BNT162b2 vaccination in a large real-life population in Denmark.METHODS: Vaccination status and positive SARS-CoV-2 RT-PCR...

Cite
Heftdal LD, Schultz M, Lange T, et al. Incidence of positive SARS-CoV-2 PCR after COVID-19 vaccination with up to eight months of follow-up: Real life data from the Capital Region of Denmark. Clin Infect Dis. 2022;doi: 10.1093/cid/ciac012.
Heftdal, L. D., Schultz, M., Lange, T., Knudsen, A. D., Fogh, K., Hasselbalch, R. B., Linander, C. B., Kallemose, T., Bundgaard, H., Grønbæk, K., Valentiner-Branth, P., Iversen, K., & Nielsen, S. D. (2022). Incidence of positive SARS-CoV-2 PCR after COVID-19 vaccination with up to eight months of follow-up: Real life data from the Capital Region of Denmark. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, . https://doi.org/10.1093/cid/ciac012
Heftdal, Line Dam, et al. "Incidence of positive SARS-CoV-2 PCR after COVID-19 vaccination with up to eight months of follow-up: Real life data from the Capital Region of Denmark." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. (2022). doi: https://doi.org/10.1093/cid/ciac012
Heftdal LD, Schultz M, Lange T, Knudsen AD, Fogh K, Hasselbalch RB, Linander CB, Kallemose T, Bundgaard H, Grønbæk K, Valentiner-Branth P, Iversen K, Nielsen SD. Incidence of positive SARS-CoV-2 PCR after COVID-19 vaccination with up to eight months of follow-up: Real life data from the Capital Region of Denmark. Clin Infect Dis. 2022 Jan 07; doi: 10.1093/cid/ciac012. Epub 2022 Jan 07. PMID: 35015858.
Copy Download .nbib Format: NLM
Synthesis of hybrid phosphorated indenoquinolines and biological evaluation as topoisomerase I inhibitors and antiproliferative agents.

Bioorganic & medicinal chemistry letters

Fuertes M, Selas A, Trejo A, Knudsen BR, Palacios F, Alonso C.
PMID: 34952177
Bioorg Med Chem Lett. 2022 Feb 01;57:128517. doi: 10.1016/j.bmcl.2021.128517. Epub 2021 Dec 21.

This work describes the first synthesis of diethyl 6,6a,7,11b-tetrahydro-5H-indeno[2,1-c]quinolinylphosphonates 5, diethyl 7H-indeno[2,1-c]quinolinylphosphonates 6 and diethyl 7-oxo-7H-indeno[2,1-c]quinolinylphosphonates 7, which were prepared in good to high overall yields. The synthetic route involves a multicomponent reaction of 2-phosphonateaniline, aldehydes and indene as...

Cite
Fuertes M, Selas A, Trejo A, et al. Synthesis of hybrid phosphorated indenoquinolines and biological evaluation as topoisomerase I inhibitors and antiproliferative agents. Bioorg Med Chem Lett. 2021;57:128517doi: 10.1016/j.bmcl.2021.128517.
Fuertes, M., Selas, A., Trejo, A., Knudsen, B. R., Palacios, F., & Alonso, C. (2022). Synthesis of hybrid phosphorated indenoquinolines and biological evaluation as topoisomerase I inhibitors and antiproliferative agents. Bioorganic & medicinal chemistry letters, 57128517. https://doi.org/10.1016/j.bmcl.2021.128517
Fuertes, María, et al. "Synthesis of hybrid phosphorated indenoquinolines and biological evaluation as topoisomerase I inhibitors and antiproliferative agents." Bioorganic & medicinal chemistry letters vol. 57 (2022): 128517. doi: https://doi.org/10.1016/j.bmcl.2021.128517
Fuertes M, Selas A, Trejo A, Knudsen BR, Palacios F, Alonso C. Synthesis of hybrid phosphorated indenoquinolines and biological evaluation as topoisomerase I inhibitors and antiproliferative agents. Bioorg Med Chem Lett. 2022 Feb 01;57:128517. doi: 10.1016/j.bmcl.2021.128517. Epub 2021 Dec 21. PMID: 34952177.
Copy Download .nbib Format: NLM
Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.

Genes & cancer

Witkiewicz AK, Cox D, Knudsen ES.
PMID: 33884103
Genes Cancer. 2021 Mar 12;12:25-27. doi: 10.18632/genesandcancer.211. eCollection 2021.

[This corrects the article DOI: 10.18632/genesandcancer.24.].

Cite
Witkiewicz AK, Cox D, Knudsen ES. Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer. 2021;12:25-27doi: 10.18632/genesandcancer.211.
Witkiewicz, A. K., Cox, D., & Knudsen, E. S. (2021). Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes & cancer, 1225-27. https://doi.org/10.18632/genesandcancer.211
Witkiewicz, Agnieszka K, et al. "Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models." Genes & cancer vol. 12 (2021): 25-27. doi: https://doi.org/10.18632/genesandcancer.211
Witkiewicz AK, Cox D, Knudsen ES. Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer. 2021 Mar 12;12:25-27. doi: 10.18632/genesandcancer.211. eCollection 2021. PMID: 33884103; PMCID: PMC8045976.
Copy Download .nbib Format: NLM
Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity.

Cancer cell

Pearson JD, Huang K, Pacal M, McCurdy SR, Lu S, Aubry A, Yu T, Wadosky KM, Zhang L, Wang T, Gregorieff A, Ahmad M, Dimaras H, Langille E, Cole SPC, Monnier PP, Lok BH, Tsao MS, Akeno N, Schramek D, Wikenheiser-Brokamp KA, Knudsen ES, Witkiewicz AK, Wrana JL, Goodrich DW, Bremner R.
PMID: 34270926
Cancer Cell. 2021 Aug 09;39(8):1115-1134.e12. doi: 10.1016/j.ccell.2021.06.016. Epub 2021 Jul 21.

Cancer heterogeneity impacts therapeutic response, driving efforts to discover over-arching rules that supersede variability. Here, we define pan-cancer binary classes based on distinct expression of YAP and YAP-responsive adhesion regulators. Combining informatics with in vivo and in vitro gain-...

Cite
Pearson JD, Huang K, Pacal M, et al. Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. Cancer Cell. 2021;39(8):1115-1134.e12doi: 10.1016/j.ccell.2021.06.016.
Pearson, J. D., Huang, K., Pacal, M., McCurdy, S. R., Lu, S., Aubry, A., Yu, T., Wadosky, K. M., Zhang, L., Wang, T., Gregorieff, A., Ahmad, M., Dimaras, H., Langille, E., Cole, S. P. C., Monnier, P. P., Lok, B. H., Tsao, M. S., Akeno, N., Schramek, D., Wikenheiser-Brokamp, K. A., Knudsen, E. S., Witkiewicz, A. K., Wrana, J. L., Goodrich, D. W., & Bremner, R. (2021). Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. Cancer cell, 39(8), 1115-1134.e12. https://doi.org/10.1016/j.ccell.2021.06.016
Pearson, Joel D, et al. "Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity." Cancer cell vol. 39,8 (2021): 1115-1134.e12. doi: https://doi.org/10.1016/j.ccell.2021.06.016
Pearson JD, Huang K, Pacal M, McCurdy SR, Lu S, Aubry A, Yu T, Wadosky KM, Zhang L, Wang T, Gregorieff A, Ahmad M, Dimaras H, Langille E, Cole SPC, Monnier PP, Lok BH, Tsao MS, Akeno N, Schramek D, Wikenheiser-Brokamp KA, Knudsen ES, Witkiewicz AK, Wrana JL, Goodrich DW, Bremner R. Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. Cancer Cell. 2021 Aug 09;39(8):1115-1134.e12. doi: 10.1016/j.ccell.2021.06.016. Epub 2021 Jul 21. PMID: 34270926.
Copy Download .nbib Format: NLM
Hybrid Quinolinyl Phosphonates as Heterocyclic Carboxylate Isosteres: Synthesis and Biological Evaluation against Topoisomerase 1B (TOP1B).

Pharmaceuticals (Basel, Switzerland)

Selas A, Fuertes M, Melcón-Fernández E, Pérez-Pertejo Y, Reguera RM, Balaña-Fouce R, Knudsen BR, Palacios F, Alonso C.
PMID: 34451880
Pharmaceuticals (Basel). 2021 Aug 09;14(8). doi: 10.3390/ph14080784.

This work describes, for the first time, the synthesis of dialkyl (2-arylquinolin-8-yl)phosphonate derivatives. The preparation was carried out through a direct and simple process as a multicomponent Povarov reaction of aminophenylphosphonates, aldehydes, and styrenes and subsequent oxidation with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone...

Cite
Selas A, Fuertes M, Melcón-Fernández E, et al. Hybrid Quinolinyl Phosphonates as Heterocyclic Carboxylate Isosteres: Synthesis and Biological Evaluation against Topoisomerase 1B (TOP1B). Pharmaceuticals (Basel). 2021;14(8)doi: 10.3390/ph14080784.
Selas, A., Fuertes, M., Melcón-Fernández, E., Pérez-Pertejo, Y., Reguera, R. M., Balaña-Fouce, R., Knudsen, B. R., Palacios, F., & Alonso, C. (2021). Hybrid Quinolinyl Phosphonates as Heterocyclic Carboxylate Isosteres: Synthesis and Biological Evaluation against Topoisomerase 1B (TOP1B). Pharmaceuticals (Basel, Switzerland), 14(8), . https://doi.org/10.3390/ph14080784
Selas, Asier, et al. "Hybrid Quinolinyl Phosphonates as Heterocyclic Carboxylate Isosteres: Synthesis and Biological Evaluation against Topoisomerase 1B (TOP1B)." Pharmaceuticals (Basel, Switzerland) vol. 14,8 (2021). doi: https://doi.org/10.3390/ph14080784
Selas A, Fuertes M, Melcón-Fernández E, Pérez-Pertejo Y, Reguera RM, Balaña-Fouce R, Knudsen BR, Palacios F, Alonso C. Hybrid Quinolinyl Phosphonates as Heterocyclic Carboxylate Isosteres: Synthesis and Biological Evaluation against Topoisomerase 1B (TOP1B). Pharmaceuticals (Basel). 2021 Aug 09;14(8). doi: 10.3390/ph14080784. PMID: 34451880; PMCID: PMC8399847.
Copy Download .nbib Format: NLM
EDITORIAL COMMENT.

Urology

Knudsen BE.
PMID: 34311926
Urology. 2021 Jul;153:80. doi: 10.1016/j.urology.2020.10.075.

No abstract available.

Cite
Knudsen BE. EDITORIAL COMMENT. Urology. 2021;153:80doi: 10.1016/j.urology.2020.10.075.
Knudsen, B. E. (2021). EDITORIAL COMMENT. Urology, 15380. https://doi.org/10.1016/j.urology.2020.10.075
Knudsen, Bodo E. "EDITORIAL COMMENT." Urology vol. 153 (2021): 80. doi: https://doi.org/10.1016/j.urology.2020.10.075
Knudsen BE. EDITORIAL COMMENT. Urology. 2021 Jul;153:80. doi: 10.1016/j.urology.2020.10.075. PMID: 34311926.
Copy Download .nbib Format: NLM
Low-dose CT for diagnosing intestinal obstruction and pneumoperitoneum; need for retakes and diagnostic accuracy.

Acta radiologica open

Larsen NE, Mikkelsen E, Knudsen AR, Larsen LP.
PMID: 33786202
Acta Radiol Open. 2021 Mar 11;10(3):2058460121989313. doi: 10.1177/2058460121989313. eCollection 2021 Mar.

BACKGROUND: One of the main concerns using low-dose (LD) CT for evaluation of patients with suspected intestinal obstruction or pneumoperitoneum is the potential need to make an additional standard-dose (SD) CT scan (retake) due to insufficient diagnostic accuracy of...

Cite
Larsen NE, Mikkelsen E, Knudsen AR, et al. Low-dose CT for diagnosing intestinal obstruction and pneumoperitoneum; need for retakes and diagnostic accuracy. Acta Radiol Open. 2021;10(3):2058460121989313doi: 10.1177/2058460121989313.
Larsen, N. E., Mikkelsen, E., Knudsen, A. R., & Larsen, L. P. (2021). Low-dose CT for diagnosing intestinal obstruction and pneumoperitoneum; need for retakes and diagnostic accuracy. Acta radiologica open, 10(3), 2058460121989313. https://doi.org/10.1177/2058460121989313
Larsen, Nis E, et al. "Low-dose CT for diagnosing intestinal obstruction and pneumoperitoneum; need for retakes and diagnostic accuracy." Acta radiologica open vol. 10,3 (2021): 2058460121989313. doi: https://doi.org/10.1177/2058460121989313
Larsen NE, Mikkelsen E, Knudsen AR, Larsen LP. Low-dose CT for diagnosing intestinal obstruction and pneumoperitoneum; need for retakes and diagnostic accuracy. Acta Radiol Open. 2021 Mar 11;10(3):2058460121989313. doi: 10.1177/2058460121989313. eCollection 2021 Mar. PMID: 33786202; PMCID: PMC7958640.
Copy Download .nbib Format: NLM
Showing 169 to 176 of 176 entries